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1. Introduction  
Clarke's Second Law is: “The only way of discovering the limits of the possible is to venture 
a little way past them into the impossible” (Clarke, 1962). Tissue Resonance InterferoMeter 
Probe (trimprob) issues this challenge. 
Cancer is a major health problem in developed countries, in many of which it is the second 
most common cause of death for all ages combined. At the beginning of the 21st century 10 
million people in the world develop cancer each year (Blackledge, 2003).  
In the Globocan 2002 database of the International Agency for Research on Cancer (IARC), 
the worldwide burden of colorectal cancer (CRC) is estimated as 550,000 incident new cases 
and 278,000 deaths for men, and 473,000 incident new cases and 255,000 deaths for women. 
In 2002, CRC comprised 9.4% of the global cancer burden in both sexes and was most 
frequent in North America, Australia, New Zealand, and parts of Europe. This has led to 
colorectal cancer being considered as a disease of the Western lifestyle (Winawer, 2007). The 
advent of molecularly targeted drugs promised to change survival. Within 20 years CRC 
will be considered a chronic disease, joining conditions such as diabetes, heart disease and 
asthma. Although very successfully used in combination, chemotherapy results in 
metastatic CRC have been disappointing with little more than palliative benefit. For 
example chemotherapy for advanced CRC cured with a low complete response and most 
patients relapsed with resistant disease (Vincenzi et al., 2004). These conditions impact on 
the way people live but will not inexorably lead to death. Individual cancer risk assessment 
will lead to tailored prevention messages and a specific screening programme to pick up 
early cancer and have far reaching public health consequences. Therefore, improving 
screening shows the challenges that need to be addressed in order to deliver most health 
benefit. But cancer prevention absorbs only 2 per cent of the total funding of cancer care and 
research in the world. Information regarding resources allocated to cancer is particularly 
scarce, even more so for CRC (Kanavos et al., 2008). CRC is rapidly increasing in Asia, but 
screening guidelines are lacking (Sung et al., 2005). Data regarding resources allocated to 
CRC in Latin America or Africa are absent. CRC expenditure adjusted for cancer population 
burden in the few countries collecting cancer expenditure, found large variations between 
countries (high of €85,116 per total cancer death in Sweden to a low of €9,528 in Russia). This 
continued with CRC expenditure, where the range was from €10,288 per CRC mortality 
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(Hungary) to €122,828 (France). Approximately half of surveyed countries had formal 
resource allocation mechanisms; fewer had disease-specific resource allocation, and only 
Australia reported cancer-specific resource allocation. The majority of countries perceived 
insufficient resources were allocated to cancer care and CRC care. Eastern European 
countries reported significant problems with cancer-specific funds, with persistent 
shortcomings and insufficient funding. Many of the countries that have formal screening 
activities, be it for CRC or other cancers, have formal screening resource allocation. 
Australia, some European countries and the USA all have governmental funding for their 
CRC screening programmes, ranging from €8-25 million. These values are half of what these 
countries allocate to their breast cancer screening programmes. It appears that cancer 
spending displays significant variation between countries, along with the majority of 
countries not accounting for cancer in its resource allocation mechanisms. As cancer 
accounts for significant morbidity and mortality after cardiovascular disease, this seems to 
be an important omission. Cancer care is a significant part of health care expenditure, and 
should be accounted and planned for appropriately.  
All these data reinforce the opinion on which the CRC is one on the most important problem 
in Healthcare. What’s the solution? The current opinion suggests to spread screening 
programmes.  
But what is a screening? Screening programmes would be developed on a national basis if 
they are simple, robust and cheap. Patients would expect the screening to take place at a 
convenient venue for them — in shopping malls and not be painful or overly time-
consuming. Health professionals would demand that any programme is accurate and does 
not give misleading results, and governments would demand that its costs would lead to 
more effective use of other resources. Novel providers of risk assessment services are likely 
to emerge. (Sikora, 2007). According to Mayo Clinic staff: “Colon cancer is cancer of the 
large intestine (colon), the lower part of your digestive system. Rectal cancer is cancer of the 
last several inches of the colon. Together, they're often referred to as colorectal cancers. Most 
cases of colon cancer begin as small, noncancerous (benign) clumps of cells called 
adenomatous polyps. Over time some of these polyps become colon cancers. Polyps may be 
small and produce few, if any, symptoms”. For this reason, doctors recommend regular 
screening tests to help prevent colon cancer by identifying polyps before they become colon 
cancer. 
Therefore it’s correct to assume that most CRCs arise from sporadic adenomas, and a few 
from genetic polyposis syndromes or inflammatory bowel disease (IBD). Because of high 
prevalence, as well as a long asymptomatic phase and treatability of precancerous lesions, 
colorectal cancer is an ideal target for screening. But these axioms cast doubts about the 
efficacy of CRC screening. 
The term “polyp” refers to a discrete mass that protrudes into the intestinal lumen, but the 
reported prevalence of adenomatous polyps, on the basis of screening colonoscopy data, is 
only in the range of 18–36%. Moreover the risk for CRC varies from country to country and 
even within countries. The risk also varies among individual people based on diet, lifestyle, 
and hereditary factors. Current guidelines are directed to test asymptomatic men and 
women who are likely to have adenomatous polyps or cancer but current CRC screening are 
efficacy only on symptomatic population. This screening always needs to be applied within 
the framework of a program that includes: primary prevention (diet, lifestyle), timely 
diagnostic work-up with colonoscopy (where available and consistent with the cascade) 
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overall in those screened positive, and timely treatment (polypectomy, surgery). CRC 
screening is particularly challenging, as reflected in current low screening rates in most 
countries where there is a high risk for CRC. CRC screening is complex, as there are 
multiple options, it requires considerable patient effort (fecal occult blood test slides, 
colonoscopy preparation, etc.), and it requires sedation and a health-care partner for some 
tests (colonoscopy). For a screening program to be successful, multiple events have to occur, 
beginning  with awareness and recommendation from the primary-care physician, patient 
acceptance, financial coverage, risk stratification, screening test, timely diagnosis, timely 
treatment, and appropriate follow-up. If any one of these steps is faulty or is not of high 
quality, the screening will fail.  
Previous studies have investigated the cost-effectiveness of colonoscopy, flexible 
sigmoidoscopy, and fecal occult blood testing as screening alternatives (Sonnemberg et al, 
2000). Flexible sigmoidoscopy was less cost-effective than fecal occult blood testing and 
colonoscopy. Fecal occult blood testing is a simple, low-cost screening method, but 
colonoscopy was more effective in saving lives. All standard options for CRC screening are 
not convincing because are cost-effective only in average-risk individuals. They are more 
cost-effective than other forms of medical screening: cholesterol in hypertension.  
 
Screening tests Evidence 
 Sensitivity Specificity  
Occult blood tests 50-60% 95.2% Fecal occult blood testing using the 
guaiac smear is currently being 
replaced in many countries by fecal 
immunochemical tests. 
Fecal DNA tests 52% 94.4% the optimal set of molecular markers 
remains to be determined, and the 
feasibility of such tests when applied 
to the general population is as yet 
unknown. 
Flexible 
sigmoidoscopy 
35-70%, 98–100% the sensitivity is low due to the 
significant number of right-sided 
adenomas that occur in the absence of 
distal tumors and are therefore missed 
on flexible sigmoidoscopy. 
Colonoscopy at least 95% 
for large 
polyps 
at least 95% 
for large 
polyps 
There are no prospective randomized 
studies that have examined the impact 
of colonoscopy on incidence or 
mortality. 
Double-contrast 
barium enema 
48% 50% It’s more likely than colonoscopy to 
yield false-positives. 
Computed-
tomographic 
colonography 
93% for 
polyps 10 
mm or 
larger 
97% for 
polyps 10 
mm or 
larger 
When polyps of all sizes were 
included, the studies were too 
heterogeneous in sensitivity (range 
45–97%) and specificity (range 26–
97%). 
Table 1. Screening tests and evidence.  
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Systematic screening colonoscopy in first-degree relatives of patients with CRC, starting at 
the age of 40, demonstrates an economic benefit only in comparison with multiple-drug 
intensive chemotherapy for advanced cancer, screening is cost-saving (Table 1). However, 
high costs and low compliance rates for colonoscopy have encouraged a search for different 
methods. It has been proposed that cancer exposed to a low level of electromagnetic 
incident waves may behave differently than healthy tissue. The phenomenon of ‘‘nonlinear 
resonance interaction,’’ which is produced when the oscillations of an electromagnetic probe 
are coupled with those from biological tissue, can be used to test for differences between 
healthy and cancerous tissues (Vedruccio et al., 2004). 
2. Electro-medical device for non invasive diagnostics  
2.1.1 Historical background 
Diagnosis of cancer in humans is mainly based on microscopic observation of morphological 
changes in cells and irregularities in tissues through the use of cytological and histological 
methods (Bibbo, 1997). All these processes are the manifestation of hidden processes of 
biochemical as well as physical nature. One of the most important as well as misleading 
effect is the Mitochondrial Warburg Effect. For a long time, disturbances in physical 
processes in cancer development were not adequately taken into consideration. To 
understand what does it mean, it’s necessary to start by the end of this process. Therapeutic 
selectivity, or preferential killing of cancer cells without significant toxicity to normal cells, 
is one of the most important considerations in cancer chemotherapy (Pelicano et al., 2006). 
Understanding the biological differences between normal and cancer cells is essential for the 
design and development of anticancer drugs with selective anticancer activity. Cancer is a 
family of diseases that involve uncontrolled cell division and tissue invasiveness 
(metastasis). In the recent years, tremendous progress has been made in our understanding 
of the molecular mechanisms of cancer, in identification of specific genes and signalling 
pathways involved in carcinogenesis and cancer progression, and in developing chemical 
compounds or specific antibodies that specifically target the oncogenic molecules.  
Cancers result from a series (progression) of gene mutations that typically involve two 
categories of function: promotion of cell division and inactivation of cell cycle suppression. 
Proto-oncogenes are normal genes that promote cell growth and mitosis, whereas tumor 
suppressor genes discourage cell growth. Proto-oncogenes can be mutated by carcinogenic 
agents to become oncogenes. Oncogenes produce excessive levels of growth promoting 
proteins. Tumor suppressor gene products typified by p53 are frequently transcription 
factors that suppress mitosis and cell growth to allow for DNA repair. Nearly half of all 
cancers involve altered p53 genes. Other suppressor genes include Rb (retinoblastoma 
family), APC (adenomatous polyposis coli), SMAD4, TP53, p16/CDKN2A and BRCA 
(breast cancer susceptibility protein) types 1 and 2. Cancer results from cumulative 
mutations of proto-oncogenes and suppressor genes which together allow the unregulated 
growth of cells. Oncogenes are typically dominant because they provide gain-of-function, 
whereas suppressor genes are recessive. They contain loss-of function mutations. Both 
copies of a suppressor gene need to mutate to cause loss-of-suppressor function. Only one 
copy of a proto-oncogene needs to mutate for gain-of-function. Mutations of tumor 
suppressor genes can be inherited. Over time malignant cells can self-select for 
characteristics that make them more malignant: ability to avoid apoptosis; immortalization 
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due to over expression of telomerase; growth-factor self-sufficiency and resistance to anti-
growth factors; increased cell division; altered differentiation; loss of contact inhibition, 
become metastatic; and able to promote angiogenesis. The target-specific agents have major 
advantages over the traditional chemotherapeutic compounds in that the targeting agents 
specifically interact with the key molecular players in cancer cells and have low toxicity to 
the normal cells. In the past researchers assumed that cancer cells and normal cells had 
much in common in terms of the internal machinery that allows them to carryout the many 
activities necessary to stay alive. Chemotherapy drugs effectively target processes that 
cancer cells need to grow and divide, such as the ability of the cancer cells to replicate their 
DNA. However, many normal cells, like the cells that line the digestive tract, also need to 
replicate. In short, though chemotherapy drugs are particularly toxic to cancer cells, they 
also damage healthy cells. The use of standard chemotherapy therefore produces many, and 
often severe, side effects. Furthermore, these side effects sometimes prevent patients from 
being able to take high enough doses to fight the cancer most effectively. While 
chemotherapy drugs are quite effective treatments for many forms of cancer, researchers 
have been working diligently to produce drugs that target the processes of cancer cells 
specifically so as to leave healthy cells unharmed. The accumulation of knowledge about the 
specific differences between normal and cancerous cells has allowed for the development of 
treatments targeted at cancer-specific activities. 
One of the most fundamental changes found in cancer cells is the presence of mutations in 
the genes that are responsible for causing cell growth (oncogenes). The defective proteins 
produced by these altered genes are prime candidates for targeted therapy. As an example, 
some cancers are caused in part by mutant proteins that send constant signals into the cell 
causing cell division. Drugs that block only the mutant form of the protein but do not 
interfere with the activity of the normal version would only affect cancer cells, and would 
leave healthy cells untouched. Alternatively, many cancers result when genes that normally 
prevent cell growth (tumor suppressors) are inactivated or turned off. Drugs that "fix" the 
activity of these proteins would repair the damaged cancer cells, but theoretically have no 
effect on normal cells. 
New agents with a high degree of target specificity and clinical therapeutic activity, 
exemplified by Gleevec (imatinib), Iressa (gefitinib), herceptin (trastuzumab), and rituximab, 
represent an exciting direction for cancer drug development. However, the mechanisms 
underlying cancer development and the disease progression are extremely complex, and it 
is now recognized that in many types of cancers there are multiple genetic and epigenetic 
alterations. Even within a specific cancer type, the malignant cell populations are 
heterogeneous and contain diverse genetic changes, which further alter over time because of 
genetic instability as the disease progresses. As such, it would be difficult to specifically kill 
these cancer cells by targeting a single gene. Proper combination of multiple target-specific 
agents may be required to effectively eliminate the entire cancer cell population.  
An alternative strategy to achieve both therapeutic selectivity and efficiency is to take 
advantage of the fundamental difference between cancer cells and normal cells in their 
biochemical metabolism. Cell proliferation requires the conversion of nutrients into biomass. 
One of the first differences noted between cancer cells and normal cells was a difference in 
metabolism (Vander Heiden et al., 2009). One of the most prominent metabolic alterations in 
cancer cells is the increase in aerobic glycolysis and the dependency on glycolytic pathway 
for ATP generation as showed in Figure 1 (Erickson & Cerione , 2010). 
www.intechopen.com
 
Colonoscopy 
 
184 
 
Fig. 1. Different metabolic pathway 
This is the Warburg effect (Warburg et al., 1924; Warburg, 1930, 1956). As this metabolic 
alteration is frequently seen in cancer cells of various tissue origins, targeting the glycolytic 
pathway may preferentially kill the malignant cells and therefore have broad therapeutic 
implications. Although cancer cell energy generation is mainly dependent on reactive 
anaerobic glycolysis, most malignant tumors still breathe, in part by an uncoupling protein-
mediated mitochondrial pathway. Uncoupling proteins help import fatty acids and are over 
expressed in various types of chemo-resistant cancer cells (Mayevsky, 2009). New 
technologies will help accomplish this systematic work.  
2.1.2 Warburg effect 
Otto Heinrich Warburg (October 8th, 1883, Freiburg im Breisgau – August 1st, 1970, Berlin), 
was a German physiologist, medical doctor and Nobel laureate. "Warburg effect" is used for 
two unrelated observations in biochemical, one in plant physiology and the other in 
oncology, As early as 1924 he demonstrated that tumor cells exhibit an altered sugar 
metabolism as they are metabolizing up to 20 times more glucose compared to healthy cells 
(Warburg et al., 1924). These cancer cells produce lactate in large amounts not only under 
anaerobic conditions (like their healthy counterparts) but also in the presence of oxygen. 
This so called “Warburg effect” or “aerobic glycolysis”. This is remarkable, since glucose 
metabolism under aerobic conditions via Embden-Meyerhof pathway (EMP), citrate cycle 
and respiratory chain yields 38 ATP per molecule glucose, while glycolysis to lactate leads 
to only 2 ATP. In the presence of oxygen and glucose, healthy cells generate a vast majority 
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of energy in form of ATP by complete combustion of glucose to CO2, while tumor cells 
metabolize the majority of glucose via pentose phosphate pathway (PPP) to lactate. 
According to standard textbooks the PPP provides cells with reduction equivalents in form 
of NADPH and moreover with ribose- 5-P, a key metabolite for DNA/RNA biosynthesis. 
The non-oxidative part of PPP is controlled by transketolase. Ever since the pioneering 
observation that aerobic glycolysis in cancer is preferred over oxidative phosphorylation as 
a mechanism to generate ATP from glucose, numerous experiments have supported and 
extended the significant role that metabolisms have on transformation, proliferation, 
angiogenesis and metastasis in cancer. Thus, scanning human tumors with positron 
emission tomography (PET) has verified that a high uptake rate of glucose constitutes a 
hallmark in cancer cells, presumably required to confer adaptive advantages when facing 
acidic and hypoxic environments. 
Normal cells use glycolysis prior to respiration in the mitochondria and complete 
breakdown of glucose by the tricarboxylic acid (TCA) cycle (Figure 1). In cancer cells, 
glycolysis becomes the primary mode of glucose metabolism resulting in lactate and its 
secretion. The M2 isoform of pyruvate kinase (PKM2) becomes tyrosine phosphorylated and 
attenuates pyruvate acetyl-CoA conversion while glutaminolysis provides the cancer cell 
with an alternate source of biosynthetic precursors, fueling the TCA cycle with glutamine-
derived α-keto-glutarate. The anti-tumor drug 968 inhibits glutamine metabolism by 
inhibiting the enzyme glutaminase (GLS). 
Cancer cells have a high glycolysis rate even in the presence of oxygen (Figure 1). Otto 
Warburg, assumed that because of mitochondrial malfunction, cancer cells had to depend 
on anaerobic glycolysis to generate ATP (Warburg, 1956). This hypothesis was later 
disproved. It was demonstrated, however, that cancer cells with intact mitochondria also 
showed evidence of the Warburg effect. This effect provides a marker for detecting tumor 
cells. With positron emission tomography using a glucose radioisotope 
(18fluorodeoxyglucose), cancer cells can be visualized owing to their significantly higher 
than normal glucose uptake. 
Thus, an alternative explanation was proposed: the Warburg effect helps cancer cells 
harness additional ATP to meet the high energy demand required for their extraordinary 
growth while providing a basic building block of metabolites for their proliferation. A third 
view suggests that the Warburg effect is a defense mechanism, protecting cancer cells from 
the higher than usual oxidative environment in which they survive. Interestingly, the latter 
view does not conflict with the high-energy production view, as increased glucose 
metabolism enables cancer cells to produce larger amounts of both antioxidants to fight 
oxidative stress and ATP and metabolites for growth. It may be related to the surprising fact 
that although aerobic respiration produces 18 times the ATP per mole of glucose compared 
with anaerobic glycolysis, the rate of anaerobic glycolysis is 100 times that of aerobic 
respiration. According to a population biology model developed at the Max Delbrück 
Center for Molecular Medicine in Germany, ATP production at a higher rate but lower yield 
may confer a selective advantage in competing for shared energy resources. Lactate, also a 
product of glycolysis, induces several oncogenes. In addition, lactate surrounds cancer cells, 
providing an acidic environment that protects cancer cells from the immune system. A key 
enzyme of the pentose phosphate pathway, transketolase, was shown to play an important 
role in cancer proliferation and malignancy. Among colon and uroepithelial cancer patients, 
the expression level of transketolase-like gene 1 (one of the transketolase genes) was 
strongly related to the patients’ survival rate. Autopsy results confirmed the correlation 
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between increased expression of transketolase-like gene 1 and a higher mortality rate 
(Langbein et al, 2006). Several factors contribute to cellular oxidative stress, which occurs 
when the balance between oxidants and antioxidants is disrupted, resulting in an overall 
increase in reactive oxygen species (ROS). ROS are produced as a result of various metabolic 
events; for example, in the formation of water molecules during mitochondrial respiration. 
Molecular oxygen (O2) is the terminal electron acceptor in the electron transport system of 
mitochondria and is converted to water (H2O). In some cases, O2 receives just one electron, 
becoming a superoxide anion. It is estimated that 4-5% of O2 molecules are normally 
converted to superoxide anions (Spitz et al, 2000). Superoxides are then converted to 
peroxides by an enzyme called superoxide dismutase. Subesquent, pyruvate scavenges the 
peroxides and converts them into water. Thus, an increased glycolysis rate that leads to 
increased pyruvate production may reduce oxidative stress.  
There are two more ways in which the Warburg effect may reduce oxidative stress. 
Mitochondrial dysfunction may result in reduced oxidative stress, given that mitochondria 
are a main source of ROS generation (Orrenius, 2007). Alternatively, the antioxidant 
production associated with the Warburg effect may protect cancer cells from the negative 
effects of their explosive glycolysis. 
Network modeling of the interconnections among the crucial factors involved in metabolic 
flow and signaling pathways is a necessary future undertaking. In addition, the 
mitochondrial uncoupling effect should not be overlooked. Although cancer cell energy 
generation is mainly dependent on reactive anaerobic glycolysis, most malignant tumors 
still breathe, in part by an uncoupling protein-mediated mitochondrial pathway (Samudio et 
al., 2007). Uncoupling proteins help import fatty acids and are over expressed in various 
types of chemo-resistant cancer cells. This may increase an apoptotic threshold level. On the 
one hand a better understanding of metabolism in cancer cells may lead to the development 
of novel therapeutic strategies exploiting their uniqueness.  
On the other current technologies may help accomplish this systematic work. In addition to 
PET and magnetic resonance, the next-generation scans is needed to precisely study cancer 
cell biochemical. As evidenced by current proteomics and biomarker studies, detection 
limits should be less than femto- to ato- mole levels, considering that significant proteins or 
small peptides secreted from a tiny tumor cell may represent only 1% of the total protein 
and are extensively diluted throughout the human body. 
2.1.3 Metabolomics 
After the pioneered study of Warburg, current research findings confirm that a major 
difference between healthy and malignant cells is the supply of energy within the cell by 
oxidative phosphorylation in the mitochondria and glycolysis in the cytoplasm. This 
biochemical assumption let to develop another innovative consideration in oncology. 
Traditional Chinese Medicine, Ayuvedic Medicine and the Ancient Greek and Roman 
Doctors all incorporated 'types' into their healing methods the idea that biological fluids 
reflect the health of an individual; with the introduction of Warburg effect it has been 
possible to think a further step: metabolic effect. During the 1940's and 50's Dr. Roger 
Williams developed the concept of 'biochemical individuality' and determined that 
"metabolic profiles" were needed to effectively evaluate and treat patients with nutrition. 
First time was born the concept that individuals might have a “metabolic profile” that could 
be reflected in the makeup of their biological fluids. The work of Williams and his group, 
however, was apparently not duplicated by others, to whom his task must have seem rather 
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herculean, with but few promises of tangible results. Hence, his ideas about the utility of 
metabolic pattern analysis remained essentially dormant until the late 1960s, when gas 
chromatography and liquid chromatography was advanced sufficiently to permit such 
studies to be carried out with considerably less effort. In this way it became feasible to 
quantitatively (as opposed to qualitatively) measure metabolic profiles. The term “metabolic 
profile” was introduced at the beginning 1970s after they demonstrated that gas 
chromatography, especially when interfaced with mass spectrometry could be used to 
measure compounds present in human urine and tissue extracts, defining the patterns of 
biochemically related metabolites (Horning, et. al. 1971). Moreover it demonstrated the 
utility of using nuclear magnetic resonance spectroscopy to detect metabolites in 
unmodified biological samples.  
In general terms the systematic study of the unique chemical fingerprints that specific 
cellular processes leave behind - specifically, the study of their small-molecule metabolite 
profiles is metabolomics. Such approach has found applications in many topics: for example 
oncology. Metabolomics have led to several successes in the field of cancer biology, such as 
the identification of new tumour subtypes, as well as transcriptional and protein biomarkers 
for certain types of cancer. Metabolic activity can also be quantified, as various analytical 
tools have been developed to measure concentrations of low-molecular-weight metabolites. 
This is a particularly challenging task as low-molecular-weight metabolites represent a 
diverse range of chemicals.  
Metabolomics has also been used to differentiate between different cancer cell lines and to 
monitor metabolic processes that occur in cancer cells during events such as apoptosis. 
Despite the successful use of metabolomics to investigate phenotypes of transgenic animals 
and plants, and its use in the pharmaceutical industry, most functional genomic studies of 
cancer have focused on transcriptomics and proteomics. Global metabolic prowling analysis 
holds the promise to permit simultaneous monitoring of precursors, intermediates and 
products of metabolic pathways. It is a research tool that can detect and monitor 
unidentified compounds as well as identified metabolites that play important roles in 
metabolism and physiology (Kaplan et al., 2004). For example metabolite profiling was used 
to characterize stress responses of potato tissue subjected to reversible electroporation, 
providing insights on how potato tissue responds to a physical stimulus such as pulsed 
electric fields (PEF), which is an artificial stress (Galindo et al, 2009). 
2.1.4 Vedruccio theory 
Today the study of biochemical interactions becomes the prevailing paradigm used to 
explain cellular functions and disease progression in oncology. Yet many biological 
questions cannot be answered with biochemical explanations alone such as the role of 
endogenously created electromagnetic fields and electrical currents in the body. In the past 
century, a great number of researchers have given their contribution to the study of the 
interactions between biological matter and electromagnetic fields. Electromagnetic fields are 
waves that transport energy through space. They are characterized by wavelength and 
frequency, the two of which are inversely correlated. Electromagnetic fields include the 
following (in order of decreasing wavelength and increasing frequency): electromagnetic 
fields of extremely low frequency (from electric sources), electromagnetic fields of low 
frequency, electromagnetic fields of radiofrequency and microwaves (from mobile 
telephones, television antennas etc), ultrasounds, infrared rays, ultraviolet rays, X rays and 
gamma rays. Since the 1970s the non thermal effects of electromagnetic fields on living 
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organisms have been well known and also the non thermal mechanisms have been 
investigated. In the case of a biochemical system we assume that each molecule can be 
labelled with a mean velocity energy which, in turn, defines an average energy associated 
with each degree of freedom of the molecule itself. In such a picture a perturbation is termed 
“thermal” if it is able to change the average kinetic energy associated to each degree of 
freedom, in such a way that the average of the energies on the ensemble is changed. The 
rotating motion of water molecules induced by microwaves is the most evident achievement 
of such a thermal effect. Electromagnetic fields and life identified several significant effects 
of the interaction of electromagnetic fields with living organisms. If living organisms 
possess the ability to utilize electromagnetic fields and electricity there must exist physical 
structures within the cells that facilitate the sensing, transducing, storing and transmitting of 
this form of energy. 
Normal cells possess the ability to communicate information inside themselves and between 
other cells. The coordination of information by the cells of the body is involved in the 
regulation and integration of cellular functions and cell growth. When cancer arises cancer 
cells are no longer regulated by the normal control mechanisms. Measurements on 
biological materials were based on resistivity or impedance and instruments such as the 
Wheatstone bridge (Presman, 1970). After the second world conflict, investigations on 
biological materials were extended into the microwave bands (Messen, 2000). In the 1920s 
Some authors discovered that both proliferating cells and cancer cells had cell membrane 
potentials that have been lower than the cell membrane potential of healthy adult cells 
(Fricke, 1926). They reported that “malignant tumors have a greater polarizability than 
normal breast tissues or benign tumors”. They carried out their experiments at low 
frequencies around 20 kHz. In cancerous tissue the electrical potential of cell membranes is 
maintained at a lower level than that of healthy cells and electrical connections are 
disrupted (Cone, 1975).  
Electric fields induce or a cause alignment in dipole movements. Most of the molecules in 
the body are electrical dipoles (Beal, 1996). These dipoles electronically function like 
transducers in that they are able to turn acoustic waves into electrical waves and electrical 
waves into acoustic waves. The natural properties of biomolecular structures enables cell 
components and whole cells to oscillate and interact resonantly with other cells. According 
to Smith and Best, the cells of the body and cellular components possess the ability to 
function as electrical resonators. A dipole movement is a function of polarization processes 
and the strength of the electric field. When biological tissue is exposed to an electric field in 
the right frequency and amplitude windows a preferential alignment of dipoles becomes 
established. Since the cell membrane contains many dipole molecules, an electric field will 
cause preferential alignment of the dipoles. This may be one mechanism that electrical fields 
alter membrane permeability and membrane functions. 
Theoretically we assume two type of electric capacity, the first is the “static capacity” that is 
independent to the frequency of the alternating current, the second is the “polarization” 
type that depends upon the interphases in the tissues and suggest that capacity might have 
a considerable biologic significance. The “polarization” capacity is related to the alternating 
current applied or irradiated to the tissue under test. Activation of cell membrane receptors 
that act as antennas for certain windows of frequency and amplitude leading to the concepts 
of electromagnetic reception, transduction. Biological organisms use weak electromagnetic 
fields (electric and photonic) to communicate with all parts of themselves. The major charge 
carriers of biological organisms are negatively charged electrons, positively charged 
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hydrogen protons, positively charged sodium, potassium, calcium and magnesium ions and 
negatively charged anions particularly phosphate ions. 
For a long time, disturbances in physical processes in cancer development were not 
adequately taken into consideration despite Warburg’s experimental discovery of 
deteriorated oxygen metabolism. Renewed interest in the Warburg effect has led to research 
on physical mechanisms in living cells. The role of mitochondrial dysfunction and 
cytoskeleton disintegration in cancer diagnostics has been recently restyling with the 
metabolic effect in metabolomics.  
There is no doubt that the pathological physical alterations express essential changes in 
cancer development. Any diagnostic method has to detect important parameters disturbed 
by cancer process. A new diagnostic method developed by Vedruccio utilizes frequency 
selective (resonant) absorption of electromagnetic waves in malignant tumors (Bellorofonte 
et al. 2005). In malignant tumors, therefore, we should expect to find structures oscillating at 
the frequencies of the emitted signals, whose dissipation is different from that of healthy 
tissue. As the measurement results do not depend on the tumor size, the electromagnetic 
resonant interactions might be assumed to take place in cancer cells. The damping of 
oscillations is significantly It has been proposed that cancer exposed to a low level of 
electromagnetic incident waves may behave differently than healthy tissue (Vedruccio et al., 
2004). The phenomenon of ‘‘nonlinear resonance interaction,’’ which is produced when the 
oscillations of an electromagnetic probe are coupled with those from biological tissue, can be 
used to test for differences between healthy and cancerous tissues. increased during cancer 
development.  
2.2 Tissue resonance interferoMeter probe 
In the 1920s the pioneers in the field of radio frequency reported that “malignant tumours 
have a greater polarizability than normal breast tissues or benign tumours”. The authors 
moreover declared that “It seems probable that the measurement of the capacity may 
provide a very practical method for diagnosing the malignancy of a tumor”. In the 1930s, 
some authors extended the frequency range of the dielectric properties of biological 
materials up to 600 MHz, by exploring the propagation of the electromagnetic waves on 
Lecher wires of variable length and which were terminated by a wire surrounding the 
biological material. The technological advances in electronic engineering following the 
second world war made possible the first work on complex permittivity measurements on 
blood cells and other biological tissues up to 30 GHz. Several years after a method which 
allowed dielectric measurements on living tissue (‘in vivo’ measurements) has been 
presented. The real time determination of complex permittivity is possible over a large 
frequency band (100 MHz – 10 GHz) by a rapid and continuous frequency scan. One such 
method is based on an antenna modeling theorem and on the application of microprocessor 
controlled microwave measurement instrumentation. A short monopole antenna is used as 
the in vivo probe. A network analyzer combined with error-correction routines and a semi-
automated data acquisition/processing system (microcomputer) is used to determine the 
real part aof the permittivity and the conductivity s of the biological tissue being analyzed. 
A non-destructive method for measuring the dielectric properties of materials by means of 
an open transmission line resonator was developed in last 1970s. In the 1980s an open-ended 
coaxial probe used to measure and compare the fractional power absorption for malignant 
tumors relative to normal adjacent tissue in rats between 30 MHz and 2 GHz. It found that 
“tumors have a greater absorption, with a broad peak, centered in the 300 – 400 MHz region”. 
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The majority of the studies cited herein refer to measurements and assessments of passive 
biophysical parameters of the tissues investigated. Measurements were of capacitance, 
resistance, complex dielectric constant.  
In 1992, while conducting research on the back coupling effects of the damping of the near 
zone electromagnetic fields on transmitter-tuned circuits, Vedruccio discovered the 
possibility of noninvasive cancer detection. The author analyzed the  perturbation of the 
electromagnetic field at the open end of a transmission line due to the dielectric material of 
unknown properties.  
In the practical application of this effect, the author first constructed some prototype pieces 
of apparatus then, proceeded to the international patent application n. WO 01/07909A1 and 
the licensing of this technology to Galileo Avionica1. The final stage is an apparatus devoted 
to medical diagnostic analysis which is CE certified with the commercial name of Trimprob . 
This method is fast and accurate up to 4 GHz. The open end of the coaxial line must be in 
direct contact with the surface of the dielectric material being investigated which has to be 
smooth and flat.  
To avoid any air gap effect, and it is necessary to apply a pressure to the material under test. 
Measurements on the human skin were given as an example because of the low penetration 
depth but, the aim was primarily therapeutic.  
Preliminary results confirmed that it was possible to observe a stimulated response in 
altered agglomerates of cells (Vedruccio, 2004). Furthermore, it offered the possibility of 
detecting responses from biological tissues. When stimulated by the particular pattern of 
electromagnetic oscillations these tissues responded in a very selective way and quite 
distinct from the previously investigated Debye and Maxwell-Wagner resonances which 
extend over decades of frequency. The principle of detection lies in the resonance between 
the coupled active nonlinear oscillator (the probe) and the passive oscillator (the tissue) in 
the radiofrequency range of the electromagnetic spectrum. The fundamental frequency of 
emitted waves is about 465 MHz. The first (930 MHz) and the second (1,395 MHz) 
harmonics are transmitted too. The probe consists of a linear oscillator fed from the 
nonlinear element T (Figure 2), together forming a nonlinear active oscillator. 
In the equivalent circuit, the oscillator is capacitively coupled to the passive one, the tissue, 
via the near field of the antenna. The tumor tissue represents a dissipative medium for the 
energy stored in the field near to source. The near field energy periodically flows out of the 
probe (the source) and returns to it.  
The frequency of the emitted signal is adjusted and locked at the point of the highest 
absorption. The receiver antenna is located beyond the immediate neighborhood of the 
source (Figure 3). In comparison with electromagnetic wave propagation without 
interaction with a tumor, the received signal at the fundamental frequency decreases about 
fivefold due to damping effects of the cancerous tissue. 
The transmitter probe with a resonant cavity incorporates a transmission line tuned to the 
frequency of oscillation, which is in the 65 cm wavelength band (465 MHz). At the open end  
 
                                                 
1 Galileo Avionica S.p.A., a Finmeccanica Company, is the Italian avionics leader. It focuses on the 
design, development and production of avionics and electro-optical equipment, space equipment for 
platform and payloads. through its Company FIAR it is a national leader in airborne radars, with 
METEOR company in tactical and training  UAVs, training simulator. Galileo Avionica offers 
cooperative programs (Eurofighter, NH-90, EH-101). in 2001 Galileo Avionica had registred a revenue 
of more than Euro millions 452. 
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Fig. 2. Hand-held, battery-operated detection probe. 
 
 
Fig. 3. Receiver, and computer display. 
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of this line, there is a semiconductor element with nonlinear characteristics that is activated 
by a nanosecond electromagnetic pulse.  
This transient provides an injection of electromagnetic energy into the tuned line, which 
performs a damped oscillation. This particular tunable amplifier-oscillator represents the 
core of the Bioscanner trimprob diagnostic device.  
It possesses lock-in or synchronization characteristics, and because of its particular 
construction, it produces a harmonically related group of coherent electromagnetic waves. 
These oscillations are radiated as a beam through the beam window of the oscillator dome 
at the end of the probe. After geometrical focusing, the beam is used to irradiate the 
investigated tissues. The probe is brought close to the investigated region. Nonlinear 
resonance interaction between the nonlinear oscillator and the tissue reduces the energy of 
the emitted wave at distinct frequencies depending on the pathological state of the tested 
tissue. This energy is measured by the spectrum analyzer, which is fed by an antenna 
situated about 2 m away from the probe. 
2.3 Clinical application  
The device is user friendly and analyses the patient fully dressed and with no discomfort. 
Diagnostic accuracy of the Bioscanner was evaluated in several clinical studies. (Bellorofonte 
et al., 2005; Da Pozzo et al., 2007; Tubaro et al., 2008; and Gokce et al., 2009) performed 
studies focused on the diagnosis of prostate cancer at 465 MHz. Trimprob diagnostic 
findings were compared to those resulting from the standard prostate cancer diagnostic 
methods including digital rectal examination, biopsy, and prostate-specific antigen (PSA) 
level. Resulting values are shown in Table 2. Data presented are consistent across studies. 
Diagnostic methods are classified by the proportion of positives and negatives correctly 
identified, i.e., by sensitivity and specificity, respectively. Prostate cancer diagnosis using 
trimprob is characterized by high sensitivity; however, the specificity is rather low. 
Bellorofonte moreover reported a significant difference between patients with benign  
 
Organ Sensibility Specificity V.P.P. V.P.N. Accuracy 
Prostate      
Tubaro (2008) 
Trimp 
86 63 60 88 72 
Tubaro (2008) 
Trimp+DRE  
96 57 59 95 72 
Bellorofonte (2005)  95 43 94 90 -- 
Bladder      
Leucci (2007) 87,5 90,5 83,3 91,1 89,5 
Breast      
Paganelli-De Cicco (2006)  84 75 -- 80 72 
Thyroid      
Sacco (2007)  100 100 -- -- 100 
Stomach-duodenum      
Mascia (2005)  93 93 95 92 -- 
Sacco  (2007)  100 100 -- -- -- 
Table 2. Clinical application 
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prostatic hyperplasia and patients with prostate cancer (Bellorofonte et al., 2005). Trimprob 
was also tested for detection of breast cancer (De Cicco et al. 2006), bladder cancer (Gervino 
et al. 2007), rectal malignant lesions (Vannelli et al. 2009), carcinomas in patients with 
multinodular goiter (Sacco et al. 2007a), and gastric cancer (Sacco et al. 2007b). According to 
the clinical experience, the trimprob seems to be a simple and reliable investigation method 
with good diagnostic results.  
The first experiments, carried out by the author in the early days of the Bioscanner invention 
and development, as well as several clinical trials during the last years, have scientifically 
validated the efficacy of the described low level e.m.f. cancer detector in several body organs 
like breast, prostate, bladder, stomach-duodenum, thyroid (Vedruccio, 2010). 
3. TRIMprob and rectal cancer 
3.1 Test principle  
The device is made of a thin probe about 30 cm long, powered by batteries and of a receiver. 
A specific software entirely elaborated by Galileo Avionica acquires, reads and manages the 
diagnostic data. The TRIMprob emits a beam of coherent  electromagnetic waves at very low 
power which tunes on the specific frequencies of the examined structures. When the 
electromagnetic field hits a biologically altered tissue, a phenomenon of interference with 
the analysed structure takes place. The trimprob system (Galileo Avionica, Turin, Italy), also 
called a Tissue Resonance InterferoMeter Probe, consists of a hand-held, battery-operated 
detection probe, a receiver, and a computer display. The probe, which is about 30 cm long, 
contains a nonlinear oscillator that generates a complex electromagnetic wave of low 
intensity with three frequency components (465, 930, and 1395 MHz) and a high degree of 
spatial and temporal coherence. Malignant and normal tissues may differ in the way they 
interact with such electromagnetic waves because proteins acquire more surface charges in 
malignant tumours, and the attraction of these charges for water molecules results in the 
presence of more ‘‘bound water’’ (Bellerofonte et al., 2005) Furthermore, dramatic changes 
in metabolism, intercellular communication, and adhesion properties of cancer cells result in 
modification of the number and nature of membrane proteins. The dipolar parts of the 
membrane proteins, which protrude from the membrane, can be reoriented by an oscillating 
electric field. The electromagnetic field produced by the nonlinear oscillator of the trimprob 
stimulates oscillations inside the tissue. When these oscillations begin to resonate, an energy 
transfer can be detected in the wave emitted by the probe. The receiver situated a short 
distance from the probe detects the change and acts as a spectrum analyzer. When the probe 
is brought near cancerous tissue, interaction with the oscillating electric field causes a 
negative amplitude change in one or more of the spectral lines. The reduction in signal 
amplitude indicates the presence of abnormal tissues and structures. The frequencies 465, 
930, and 1395 MHz were previously determined to be optimal because they appeared to 
respond in the appropriate way to the resonances of the system. 
3.2 Test procedure  
The test was performed for each individual patient according to the procedure shown in 
Figure 4. The patient stood between the operator and the receiver, at a distance of 120 cm 
from the receiver. There was a single operator, who was not blinded to the results of the 
colonoscopy, because the endpoint was the feasibility of this device. The patient was 
dressed normally, but no metallic objects were allowed on his or her person, and no 
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electronic devices were admitted in the test area. The pelvic area was scanned by moving 
the detector at close contact over the pelvic surface through six planes, first in three 
directions (axial, left, and right) with the patient facing the receiver and then repeating the 
process with the patient turned to face the operator. The test was performed for each 
individual patient according to the procedure. The detector was kept in close contact with 
the pelvic surface and was moved through six planes: A1, posterior right lateral; A2, 
posterior median; A3, posterior left lateral; B1, anterior right lateral; B2, anterior median; B3, 
anterior left lateral. There was a single operator, who was not blinded to the results of the 
colonoscopy, because the endpoint was the feasibility of this device. The patient was 
dressed normally, but no metallic objects were allowed on his or her person, and no 
electronic devices were admitted in the test area. In this way, a scan of the whole pelvis 
volume was obtained with signal acquisition at six positions: posterior median, left lateral, 
and right lateral; and anterior median, left lateral, and right lateral. Each change in 
amplitude of the emitted signals at the established frequencies was recorded and stored in 
an electronic file as a value of the corresponding spectral line expressed in arbitrary units 
between 255 and 0. Thus, three numeric values, corresponding to the signal amplitude of the 
spectral lines for the frequencies 465, 930, and 1395 MHz, were obtained for each position.  
 
 
Fig. 4. Trimprob procedures. The detector was kept in close contact with the pelvic surface 
and was moved through six planes: A1, posterior right lateral; A2, posterior median; A3, 
posterior left lateral; B1, anterior right lateral; B2, anterior median; B3, anterior left lateral. 
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The test was performed for each individual patient according to the procedure. The detector 
was kept in close contact with the pelvic surface and was moved through six planes: A1, 
posterior right lateral; A2, posterior median; A3, posterior left lateral; B1, anterior right 
lateral; B2, anterior median; B3, anterior left lateral. The patient stood between the operator 
and the receiver, at a distance of 120 cm from the receiver. There was a single operator, who 
was not blinded to the results of the colonoscopy, because the endpoint was the feasibility of 
this device. 
The patient was dressed normally, but no metallic objects were allowed on his or her 
person, and no electronic devices were admitted in the test area. 
4. Remarkable experiments  
4.1 Introduction   
Population screening programs for the early diagnosis of CRC have the potential to reduce 
the incidence and mortality from this disease. Most of these programs are based on stool 
tests or structural exams (Vannelli et al., 2010). The main purpose of the screening should be 
to detect 90% of the sporadic cases of CRC. In a health care system with unlimited financial 
resources the choice of the type of screening and the suitable population for this 
examination does not represent a problem. Everywhere, even though there are different 
health care systems, financial resources are limited and the rectal screening with the current 
methods could be applied only to a selected population. On the other hand, the majority of 
adults are not receiving regular age- and risk-appropriate screenings or have never been 
screened at all (Zampino et al., 2009). Despite the fact that the primary barriers to screening 
are lack of health insurance, lack of physician recommendation, and lack of awareness of the 
importance of RC screening, the historical evidence shows that adults have different 
preferences and patterns of use among the available CRC screening tests. Thus, a less 
expensive, faster, and less invasive RC screening procedure with a similar or better efficacy, 
as compared to available methods, would provide a significant advantage for RC prevention 
in the general population. We recently carried out a pilot study for the identification of RC 
by electromagnetic detection, a method that is rapid, non-invasive, and inexpensive. As 
compared to the results of colonoscopy, electromagnetic detection of rectal cancer was 
highly specific (85%) and highly sensitive (94%) (Vannelli et al., 2009). Herein, by a 
prospective study we evaluated the prediction accuracy of CRC by electromagnetic 
detection. A pilot study has been carried out for the identification of CRC by 
electromagnetic detection, a method that is rapid, non-invasive, and inexpensive (Vannelli 
et al., 2009). A subesquent  study protocol was approved by the Institutional Review Board 
and Ethics Committee of the Fondazione IRCCS “Istituto Nazionale Tumori” Milano. The 
ClinicalTtrials.gov ID of the study is: NCT00963794. This study was carried out using a 
blind and a prospective design, with patients undergoing electromagnetic detection 
followed by colonoscopy. 
4.2 Preliminary results   
We hypothesized to adapt trimprobe in early detection-screening for rectal cancer. Of 1,792 
patients admitted to our outpatient clinic from March to September 2006 because of 
gastrointestinal disease, 756 patients underwent colonoscopy and were evaluated for 
possible participation in the Trimprob study. Exclusion criteria consisted of age younger 
than 18 years, history of psychiatric illness, and preoperative radiotherapy. To rule out 
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possible interference with the electromagnetic field, we also excluded patients with active 
phlogistic processes, such as inflammatory bowel disease, anal abscess, or fistulas. To rule out 
possible interference from other types of altered tissues, we included only the rectum, with a 
cut-off 15 centimetres from the anal verge. A total of 228 patients (113 females and 115 males) 
were selected for participation in the study: 114 patients with negative colonoscopy results and 
114 patients with colonoscopy positive for rectal cancer. Written informed consent was 
obtained from all subjects. The study protocol was approved by the Institutional Review Board 
of the Fondazione IRCCS “Istituto Nazionale dei Tumori” Milano. 
4.3 Clinical trials 
After the encouraging results we decide to prepare a prospective randomized clinical trial. 
442 patients have been admitted to our outpatient's Department from January to August 
2008 because of gastrointestinal disease or clinical symptoms related to colorectal risk. 
Exclusion criteria consisted of age younger than 18 years, history of psychiatric illness, and 
preoperative radiotherapy: 27 patients. Under written informed consent, 415 subjects were 
recruited consecutively (10 patients refused the protocol). All subjects underwent 
electromagnetic detection of RC, followed by colonoscopy. The patients completed the 
examination with computed tomography (positive colonoscopy) or abdominal sonography 
(negative colonoscopy). The device lets the examination limited to the pelvis and we 
regarded the rectum cutoff within 15 cm from the anal verge. Biopsy of suspected neoplastic 
lesions and histopathological exam of the eventual lesions were performed (209 patients), 
showing that 108 patients carried a rectal cancer whereas 101 patients carried a cancer in the 
upper gastrointestinal tract (right or left colon); these latter patients were excluded from this 
study (Table 1). The study protocol was approved by the Institutional Review Board and 
Ethics Committee of the Fondazione IRCCS “Istituto Nazionale dei Tumori” Milano. The 
ClinicalTtrials.gov ID of the study is: NCT00963794. 
5. Phenomenon interpretation 
No adverse effects of the Trimprob procedure were observed in the two trials. The 
procedure was performed in a short time (approximately 10 minutes) and was well accepted 
by all patients. In first trial, only the first spectral line, at the 465-MHz frequency, 
differentiated the group with positive colonoscopy from that with negative colonoscopy in 
all six probe positions (P < 0.001). At 930 MHz, the two groups differed significantly only in 
the posterior right, posterior median, posterior left, and anterior left positions; no significant 
differences were seen at 1395 MHz. To evaluate the applicability of trimprob 
electromagnetic signal as a marker for distinguishing between CRC and non-CRC disease 
groups, we performed Receiver Operating Characteristic (ROC) curve analysis. Figure 5 
shows the curves ROC calculated for each frequency. Only the 465-MHz frequency had an 
AUC-ROC value close to 1 (0.94), indicating good discrimination between positive and 
negative colonoscopy at this frequency. In contrast, 930 MHz and 1395 MHz had AUC-ROC 
values close to 0.5, indicating poor discrimination. ROC curve showed the diagnostic ability 
of trimprob electromagnetic signal in the differentiation of RC patients versus non-cancer 
subjects (AUC = 0.96, 95% confidence interval (CI) 0.94 - 0.98; P < 2.2e-16). In our cohort, the 
sensitivity of the trimprob device for RC was 0.94, specificity was 0.84, negative predictive 
value was 0.88, positive predictive value was 0.92, and accuracy was 0.90 for the 
electromagnetic signal cut-off value of 50 U. Indeed, an electromagnetic signal < 50 arbitrary 
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units (U) was significantly associated with detection of RC by colonoscopy (p < 2.2e-16). 
Analysis of accuracy by cut-off value indicated that ~50-55 U represent the best cut-off 
values for detection of RC. Second trial of 442 subjects enrolled at our Institute due to signs 
of CRC risk was carried out using a blind and a prospective design, with patients 
undergoing electromagnetic detection followed by colonoscopy. Histopathologic analysis of 
biopsies revealed that all CRC cases were of the adenocarcinoma histotype. Data from 196 
patients with negative colonoscopy results and 108 patients with rectal cancer by 
colonoscopy were available for analysis. The median patient age was 65 (range, 24-84) years 
for the negative colonoscopy group and 65 (range, 22-85) years for the positive colonoscopy 
group. All patients with a CRC diagnosis have been subjected to computed tomography, 
which revealed 9 liver metastasis and no other primitive cancer types. All patients with 
positive colonoscopy were admitted to the hospital with a diagnosis of rectal 
adenocarcinoma and submitted to surgery. Patients not carrying a CRC, (exception of 13 
subjects), have been subjected to abdominal sonography, which revealed no cancer 
pathology. However, 10 patients revealed active phlogistic processes: 6 inflammatory bowel 
disease, 1 anal abscess and 3 fistulas. Since PSA levels were not measured as a screening for 
prostate cancer, this may be a possible limitation to the study results.  
 
 
Fig. 5. ROC curve 
CRC patients classified by colonoscopy showed a significantly lower electromagnetic signal 
than did non-CRC subjects, i.e., 40.9 ± 0.9 U (mean ± S.E.) versus 79.2 ± 1.4 U (Figure 6). To 
evaluate the applicability of Trimprob electromagnetic signal as a marker for distinguishing 
between RC and non-RC disease groups, we performed ROC (Receiver Operating 
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Characteristic) curve analysis. ROC curve showed the diagnostic ability of trimprob 
electromagnetic signal in the differentiation of RC patients versus non-cancer subjects (AUC 
= 0.96, 95% confidence interval (CI) 0.94 - 0.98; P < 2.2e-16). In our cohort, the sensitivity of 
the trimprob device for RC was 0.94, specificity was 0.84, negative predictive value was 0.88, 
positive predictive value was 0.92, and accuracy was 0.90 for the electromagnetic signal cut-
off value of 50 U. Indeed, an electromagnetic signal < 50 U was significantly associated with 
detection of RC by colonoscopy (p< 2.2e-16, Table 3). Analysis of accuracy by cut-off value  
 
 
Fig. 6. Lower electromagnetic signal associated with rectal cancer carrier status. P < 2.2e-16, 
Kruskal-Wallis test.  
 
Electromagnetic signal score Number of subjects with 
P b 
Non-CRC a CRC a 
≥50 184 17  
<50 12 91 <1.0e-16 
    
≥70 134 0  
<70 62 108 <1.0e-16 
    
a By colonoscopy analysis. b Fisher’s exact test. 
Table 3. Association between electromagnetic score settled out at different thresholds and 
the CRC disease status defined by colonoscopy. 
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indicated that 50-55 U represent the best cut-off values for detection of RC. Since a major 
goal in screening tests is the minimization of false-negative rates, we identified an 
electromagnetic threshold, i.e., < 70 U, at which no RC was missed (Table 3). However, at 
this threshold, 62 (31.6%) of the non-RC subjects were false-positive (Table 3), whose disease 
or healthy status would have required clarification by colonoscopy. No association between 
nodal involvement (N0 versus N ≥ 1) and the value of the electromagnetic signal was 
observed. A significant inverse correlation was observed between the size of the neoplastic 
lesions and the value of the electromagnetic signal (Spearman's rho = -0.290, P = 0.002), 
whereas a significant positive correlation was found between increasing distance from anal 
verge and the value of the electromagnetic signal (Spearman's rho = 0.362, P = 0.0001). 
6. Discussion  
Since up to 10% of the general population might carry a RC, depending on the age of the 
population undergoing screening, new easy and non-expensive methods for population 
screening for RC may be helpful for early detection of such disease. The most frequently 
used screening methods for RC include two general categories: stool tests (tests for occult 
blood or exfoliated DNA) and structural exams [endoscopy, double-contrast barium enema 
and computed tomographic colonography (CTC)]. The popular occult blood test is 
characterized by simplicity, non-invasiveness, and demonstrated mortality benefit but 
suffers from poor sensitivity, low population compliance, and high costs of follow-up for 
false-positives. Indeed, in a large study of asymptomatic patients who underwent occult 
blood testing followed by endoscopy, the sensitivity of the occult blood test for identifying 
advanced neoplasia was only 24% . Compared to the occult blood test, CTC is much more 
expensive, whereas this technique has some clear advantages when compared to endoscopy 
since it is non-invasive, less time-intensive and is associated with a lower risk of 
complications. However, CTC requires the use of ionizing radiations, a high level of 
expertise in reading, and has shown wide variations in sensitivity in the various clinical 
trials (Vannelli et al., 2010). Endoscopy is an invasive, lengthy and expensive procedure 
requiring adequate clinical infrastructure and medical expertise, and is not without 
complications. Thus, it represents even a relatively "poor screening" method for RC at the 
general population level, especially as compared with screening methods, such as the PAP 
test, for other types of cancer. The ageing of the general population in the Western world, 
with the consequent increase of people at risk of RC, further makes large screening 
programs based on colonoscopy unfeasible. Still, early detection of RC can save lives and 
can also decrease the cost of the patient's clinical management, since patients with early 
neoplastic lesions require simpler surgical resections and treatments than those with 
advanced disease. Although endoscopy is generally safe, it is still an invasive procedure 
with several-fold higher rates of serious complications than for any other commonly used 
cancer screening test. Repeated examinations over time may incur a substantial cumulative 
rate of complications. In addition, a relatively small risk (2 to 6%) of RC remains 6 to 36 
months after negative colonoscopy, especially when internists and family practice 
physicians rather than gastroenterologists perform endoscopies. However, in the near term, 
even greater incidence and mortality reductions could be achieved if a greater proportion of 
adults received regular screening. Although prospective randomized trials and 
observational studies have demonstrated mortality reductions associated with early 
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detection of invasive disease, as well as removal of adenomatous polyps, a majority of 
adults are not receiving regular age and risk-appropriate screening or have never been 
screened at all. Recent interest has focused on use of trimprob for diagnosis of disease as 
new screening strategy. This technique is characterized by simplicity, efficacy, and good 
patient compliance. In the present prospective study, patients with CRC diagnosed by 
colonoscopy and histopathologic analysis showed significantly lower values of the 
electromagnetic signal as compared to non-CRC patients. At a signal threshold of 50 U, 
defined by our previous study as the optimal threshold in discriminating CRC from non-
CRC patients, the electromagnetic detection showed a highly significant association with the 
CRC status, thus confirming in an independent cohort our previous findings. This 
technology has also been investigated on other cancers, in particular prostate cancers with 
favourable outcomes. The observed inverse correlation between the size of the neoplastic 
lesions and the value of the electromagnetic signal is consistent with the association between 
low electromagnetic signal values and high probability of CRC, and raises the possibility 
that CRC size represents a factor affecting the sensitivity of CRC electromagnetic detection. 
The positive correlation observed between increasing distance from anal verge and the 
value of the electromagnetic signal may reflect a decreasing detection power of the device 
with distance of the lesion or, alternatively, with interference of anatomical structures in the 
anal region. Further studies are needed to clarify the existence of a dimensional threshold or 
of a minimal distance from anal verge of CRC to be detected by electromagnetic signal. 
Notwithstanding the highly significant association between electromagnetic detection and 
CRC status observed using the 50 U signal threshold, the frequency of false-negative results 
at this threshold was relatively high (15.7%,) and, although much less than the frequency of 
missing CRCs by the fecal occult blood test, too high for population-based CRC screening. 
By increasing the signal threshold value to 70 U, we can avoid all false-negative findings in 
our cohort, thus we can correctly identified all CRC cases but increased the frequency of 
false-positives to about 30% of the non-CRC subjects. Thus, follow-up colonoscopy in real- 
and false positive subjects would be necessary to characterize the subject's disease status. 
We are aware of the limitations of our study, since the relatively small size of our series and 
the consequent low detection power. Also, trimprob was never tested in a multicentric 
study for the detection of CRC and control subjects from general population, without any 
gastrointestinal symptoms related to CRC risk, have not been tested. Other possible 
limitations that have not been addressed in the present study include operator dependence 
and the effects of other gastrointestinal diseases. 
7. Conclusion  
Our present findings point to the promise of electromagnetic detection as a simple, accurate, 
and inexpensive tool for early detection of CRC in cancer prevention programs at the 
general population level. However, the present results represent only a first step and studies 
in large cohorts and in different populations are needed to further compare the usefulness of 
this method with other CRC screening methods, especially colonoscopy. In addition, the 
description of benefits is complicated by different performance characteristics of the variants 
tests. Moreover, test performances in research settings and in clinical practice may vary. 
Therefore, we can imagine in the future the possibility to support the common screening 
tests with electromagnetic detection. 
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